2023-04-24 10:15:18 ET
IN8bio ( NASDAQ: INAB ) stock rose ~110% on Monday after the company reported data from a phase 1 trial of INB-100 in patients with leukemia.
The company said that data showed that 100% of evaluable patients (n=7) on INB-100 remained alive, progression-free, and in durable complete remission (CR) as of April 21.
INB-100 achieved durable 100% CR in treated patients, including patients with high-risk acute myeloid leukemia (AML) and a patient with acute lymphoblastic leukemia (ALL) who had failed 4 prior lines of treatment, including CAR-T.
The evaluable patients remained alive at last assessment and one patient beyond 3 years, according to the company.
Additional treated patients have remained progression free for 33.9, 22.2, 7.8, 5.8, 5.6 and 2.6 months, respectively, the company noted.
In addition, IN8bio said that data showed that allogeneic gamma-delta T cell expansion and persistence continued up to 180 days post-therapy, marking the first-ever show of this type of response in an allogeneic cellular therapy.
IN8bio added that safety data reported low-grade (1-2) graft versus host disease (GvHD) in all patients treated, which was steroid-responsive, and had a more rapid onset at higher dose levels.
"We are thrilled to report that 100% of evaluable dosed patients remain in morphological CR with the first three high-risk AML patients with complex cytogenetics now alive and relapse-free, with one patient surviving for as long as 3 years," said IN8bio's Chief Medical Officer Trishna Goswami.
No dose limiting toxicities were seen and the company has selected Dose Level 2 as a phase 2 dose.
For further details see:
IN8bio stock surges ~110% as blood cancer drug INB-100 shows promise in phase 1 trial